Catalyst

Slingshot members are tracking this event:

Theravance Biopharma (TBPH) and Celgene (CELG) initiate Phase 2a clinical trial of TD-6450 to treat patients with Hepatitis C virus

Source Link:
http://seekingalpha.com/article/3612436-theravance-biopharmas-cryptic-new-partnership-celgene

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CELG
100%
TBPH
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details the author of the article is long on TBPH
http://seekingalpha....
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 28, 2015
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2a, Phase 2 Clinical Trial, Hepatitis C, Td-6450
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.